Irland - Englisch - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - fentanyl - transdermal patch - 75 micrograms/hour - phenylpiperidine derivatives; fentanyl

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

par pharmaceutical inc. - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 25 ug in 1 h - fentanyl transdermal system is contraindicated in the following patients and situations: clinical considerations fetal/neonatal adverse reactions prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. observe newborns for symptoms of neonatal opioid withdrawal syndrome, such as poor feeding, diarrhea, irritability, tremor, rigidity, and seizures, and manage accordingly [see warnings precautions (5.4)]. teratogenic effects pregnancy c: there are no adequate and well-controlled studies in pregnant women. fentanyl transdermal system should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. the potential effects of fentanyl on embryo-fetal development were studied in the rat, mouse, and rabbit models. published literature reports that administration of fentanyl (0, 10, 100, or 500 mcg/kg/day) to pregnant female sprague-dawley

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 16.8mg;   - transdermal patch - 100 mcg/h - active: fentanyl 16.8mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 2.1mg;   - transdermal patch - 12 mcg/h - active: fentanyl 2.1mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 4.2mg;   - transdermal patch - 25 mcg/h - active: fentanyl 4.2mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 6.3mg;   - transdermal patch - 37 mcg/h - active: fentanyl 6.3mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 8.4mg;   - transdermal patch - 50 mcg/h - active: fentanyl 8.4mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 12.6mg;   - transdermal patch - 75 mcg/h - active: fentanyl 12.6mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

dispensing solutions inc. - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 25 ug in 1 h - fentanyl transdermal system is indicated for management of persistent, moderate to severe chronic pain that: - requires continuous, around-the-clock opioid administration for an extended period of time, and - cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids fentanyl transdermal system should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see dosage and administration ). patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for use on an as needed basis (i.e., prn

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - fentanyl (unii: uf599785jz) (fentanyl - unii:uf599785jz) - fentanyl 25 ug in 72 h - fentanyl transdermal system is indicated for management of persistent , moderate to severe chronic pain that: - requires continuous, around-the-clock opioid administration for an extended period of time, and requires continuous, around-the-clock opioid administration for an extended period of time, and - cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids. cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids. fentanyl transdermal system should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/h (see dosage and administration ). patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg o